Skip to main content
Equibles

Jan van de Winkel

CEO

Genmab A/S (GMAB)

Chairman

Personal wealth note: Equibles reports source-backed professional activity and disclosed compensation; it does not estimate personal net worth.

About Jan van de Winkel

Jan van de Winkel is recorded as CEO at Genmab A/S (GMAB). The company reported in an 8-K filed August 30, 2024 that Jan van de Winkel resigned as director, effective August 30, 2024. Jan van de Winkel has spoken on 23 earnings calls and 1 other investor event across 1 company, most recently for Genmab A/S on September 15, 2026.

“On August 27, 2024, Jan van de Winkel, Ph.D., notified HOOKIPA Pharma Inc. (the “Company”) of his resignation as a director of the Company, effective as of August 30, 2024 at 12:00 p.m. Eastern Time (the “Effective Time”).”
Company Form 8-K, filed August 30, 2024 · Read the filing

Summary generated from SEC filings and earnings-call records held by Equibles.

Affiliation history

Recorded current and former roles; source labels appear when available.

  • Genmab A/S (GMAB)

    CEO

    Source not stated

    Current

  • Organization not stated

    Chairman

    Proxy statement

    Current

    Start not stated–present

Company network

Recorded roles and call appearances connecting this person to public companies.

Company

Current role

Chairman

Recent activity

Earnings-call and investor-event appearances, plus filed executive appointments or departures, newest first.

Show 13 earlier activities